#mortality

A second meta-analysis found that people with cirrhosis had higher COVID mortality.

Most outcomes were similar in lean and heavy people with fatty liver disease, but the lean group had higher liver-related mortality.

People treated with direct-acting antivirals had a lower risk for liver failure and liver cancer as well as much lower mortality.

Experts predict that more than a million people could die from liver cancer worldwide in 2040.

People with hepatocellular carcinoma had improved survival after the advent of direct-acting antiviral therapy.

Over the past decade, deaths related to HBV rose significantly in West Virginia and Kentucky.

Plus: Study shows that cutting down on alcohol consumption can reduce cancer risk.

The pandemic also disrupted medical care and had an indirect effect on other causes of death.

Viral hepatitis is linked to adverse outcomes in pregnant people, underscoring the need for hepatitis B and C screening.

People with fatty liver disease and advanced fibrosis also had a greater incidence of diabetes.

The MAFLD criteria for diagnosis was linked to higher all-cause and cardiovascular mortality.

People under 50 who were cured of hepatitis C were at comparable risk to the general population.

Study finds that lean people with NAFLD had a higher risk for liver events, cancer and mortality.

One in five counties had an increase in deaths from hepatitis C, even as the nation experienced a general decline in mortality rates.

The decrease is largely due to improved lung cancer treatment, but the impact of COVID-19 is not yet known.

The hep C mortality reduction goal will not be met by any state, according to recent projections.